Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

A test for predicting the efficacy of common platinum drugs enabling personalized chemotherapy for bladder cancer patients.

Funder: European Commission

Funding period
EUR 50 K
USD 55 K
Funding amount
Abstract
Platinum-based chemotherapy is the primary therapeutic intervention for over 500,000 patients per year in the EU. Although some patients are cured by this type of chemotherapy, as many as 75% of lung cancer patients and 60% of bladder cancer patients show no benefit and could be more appropriately given alternative treatments, and therefore over €4bn annually is wasted on unnecessary treatments. There is a need for a rapid, accurate test to distinguish those patients who are likely to respond to chemotherapy and those who are not.
Accelerated Medical Diagnostics aim to personalise chemotherapy for cancer patients through their own developed PlatinDx assay, which can be used to identify those patients which are appropriate for platinum-based chemotherapy. Cancer patients are given a microdose (1% of the therapeutic dose) of a platinum-based drug, followed by quantitation of drug-DNA adducts in biopsy tissye using accelerator mass spectrometry (AMS). Levels of drug-DNA damage are measured by AMS in white blood cells and tumor biopsy tissue, which are used as a predictor of therapeutic response.
Within the innovation project Accelerated Medical Diagnoistics intend to: gain medical certification within the EU; run a scaled up clinical trial to gain significant results; and adress the EU market and launch their service in the EU.
Similar projects All >
Sorted by: Start Date
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Bladder cancer chemotherapy potentiation with a multiprong arachidonic acid pathway modulator

National Cancer Institute to PAUL THOMAS HENDERSON

USD 300,000
2019 - 2020
Project list item
New zebrafish-based methods for prediction of cisplatin response in bladder cancer

VINNOVA to Lasse Jensen

USD 31,725
2019 - 2019
Project list item
[Development of myeloid-derived suppressor cells (MDSC) targeted therapy for the treatment of bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to 祐士 武山

USD 38,310
2019 - 2023

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Lung Cancer

  • RCDC

    Lung

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • HRCS RAC

    5.1 Pharmaceuticals

  • HRCS RAC

    6.1 Pharmaceuticals

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science